Safety of MODI Insulin Algorithm for Adults with Diabetes

This study is testing the safety of the MODI Algorithm, a new tool to help manage insulin doses, for adults with type 1 or type 2 diabetes. The MODI Algorithm includes a diary app to view treatment plans and log events like insulin intake and meals, plus a bolus calculator. You might be able to join if you are between 18 and 80 years old, have had diabetes for at least six months, and use insulin therapy. The main goal is to see how well MODI helps keep your blood sugar from going too low (below 54 mg/dL) over 13 weeks. The study plans to enroll 102 participants, but its current recruitment status is unclear.

Study design
This is a single-arm study, meaning all participants will receive the MODI Algorithm. It will involve 102 adult participants with type 1 or type 2 diabetes.
What's involved
You will use the MODI insulin titration algorithm and a diary app for 13 weeks, following a 2-week period of your usual therapy.
Compensation
Not stated in the trial record.
Follow-up
The primary safety measure is assessed at 13 weeks, indicating the duration of the intervention phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07599982

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

Recruiting
NAAges 18–80InterventionalTreatment
DreaMed Diabetes
~102 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:MODI Algorithm

At a glance

Recruiting sites
5 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
CGM-measured percent time <54mg/dL
Measured over 13 weeks
Type 1 Diabetes (T1D)
Type 2 Diabetes (T2D)
6 sites across 6 states
Maryland1
Michigan1
New York1
North Carolina1
Texas1
Utah1

Opens a ready-to-send draft in your own email app — review before sending.

  • CGM-measured percent time <54mg/dL13 weeks

    Change in CGM-measured percent time \<54 mg/dL from 2 weeks of baseline to 4 weeks prior to the dose guidance week 12 visit (non-inferiority with margin 0.5%)